Oligonucleotide

We have a model that we call Togo.

That model does one really simple thing that's super important to any family that's gotten the diagnosis, and that is taking in that genetic information and looking across active approved therapies, clinical trials, off-label opportunities, as well as novel genetic medicines like we're talking about here, ASOs, gene editing, gene therapy, looking at all those different options comprehensively based on the patient's own data and background and recommending to them that these are the ones that might make sense.

And that process usually today either does not happen at all, and a, a patient is left to go Google or ChatGPT that type of information, um, which often has lots of, you know, errors or gaps, um, or, um, it, you know, it's happening very, very slowly.

You know, a team of MD PhDs is reviewing by hand a patient's eligibility for a novel genetic therapy, and that can take up to fifty hours o-of their time, which just simply does not scale.

Um, the same way that you would hire one general contractor if you wanted to build a house, instead of trying to go find the best plumber, the best electrician, so on and so forth.

We take that on, we manage all that, and we're the single point of truth for the patient.

Right now, we've got a double-digit number of genetic medicine programs across neurology and retinal disease, and we are working in both ASOs as well as gene therapies.

Um, all of our programs are preclinical right now, and that's 'cause we just started opening our gates to patients at the start of this year, twenty twenty-six.

Let me just ask you one other question.

ASOs work more in the nucleus of the cell versus the siRNAs that work in the cytoplasm.

Do you think that matters at all?

It's a great point.